ÂÜÀòÂÒÂ×

Michael Lark is currently an advisor at BioAdvance, and previously held the position of Project Leader at BioMotiv from June 2018 to December 2019. Prior to that, they were the CSO and Sr. VP of Research at Trevena, Inc. from February 2008 to December 2017. Michael has also held positions at Evol Science, Moulder Center for Drug Discovery Research, Ophidion Bio, and Mirata Pharmaceuticals.

Lark has played a key role in private financing activities as well as a leadership role in Trevena's successful IPO. Michael is responsible for developing and executing the scientific strategy which delivered four differentiated product candidates into clinical development. Michael has also led the oliceridine cross-functional project team which took the compound from discovery through clinical development, culminating in an NDA file in late 2017.

Michael Lark received their PhD in molecular biology and microbiology from Case Western Reserve University School of Medicine.